Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

A Regeneron/Sanofi team has a target date for launching the world’s 6th PD-1/L1 checkpoint inhibitor. And while they may be late to the growing league of rivals — dominated by Bristol-Myers Squibb and Merck — they plan to enter with a market splash, with considerable assistance from FDA regulators who are steel keen to expand the field.